NASDAQ$SLDB
Solid Biosciences Inc · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Solid Biosciences reported financial results for Q1 2022 and updated corporate strategy.
Solid Biosciences announced an update to its strategic priorities to focus on developing SGT-001 and SGT-003. The company reported a net loss of $25.3 million for the first quarter of 2022 and had $180.1 million in cash, cash equivalents, and available-for-sale securities as of March 31, 2022.
- Focusing on developing SGT-001 and SGT-003 pipeline programs for Duchenne Muscular Dystrophy.
- Transitioning SGT-001 to a commercially scaled transient transfection-based manufacturing process.
- Advancing SGT-003 toward an anticipated IND submission in early 2023.
- Reorganization will result in a reduction in planned corporate expenditures which is anticipated to extend funding of operations through important clinical milestones and into Q2 2024.
Headline financials
Revenue & EPS history
Solid Biosciences · Revenue · Quarterly
$1.93M
Forward guidance
Solid Biosciences anticipates that the use of transfection-based manufacturing processes for both SGT-001 and SGT-003 will allow the company to focus its operating structure and better leverage external manufacturing expertise.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2022
-3.2%
Avg return
Earnings day
+0.7%
Avg return
5 days after
+3.1%
Avg return
30 days after
50%
16 / 32 earnings
Positive
+19.0%
Q2 2019
Best reaction
-72.2%
Q3 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +2.0% | +14.2% | +14.7% | |
| Q3 2025 | +7.4% | +15.3% | +46.8% | |
| Q1 2025 | +8.3% | +14.2% | +71.2% | |
| Q4 2024 | +5.3% | -9.6% | -50.5% | |
| Q3 2024 | -2.9% | +0.8% | -15.0% | |
| Q2 2024 | +16.6% | +23.9% | +7.8% | |
| Q1 2024 | -6.6% | -8.4% | -20.7% | |
| Q4 2023 | +7.7% | +17.2% | -9.0% | |
| Q3 2023 | -23.9% | -22.9% | +80.7% | |
| Q2 2023 | -1.1% | -1.1% | -12.9% | |
| Q1 2023 | +1.9% | +1.0% | +2.3% | |
| Q4 2022 | -2.6% | +5.0% | +28.6% | |
| Q3 2022 | +3.9% | +4.6% | -0.8% | |
| Q2 2022 | +6.5% | +15.3% | -10.8% | |
| Q1 2022 | -24.2% | -29.0% | -23.9% | |
| Q4 2021 | -7.0% | +34.0% | -0.9% | |
| Q3 2021 | +13.9% | +3.7% | -21.8% | |
| Q2 2021 | -3.0% | -7.1% | -1.1% | |
| Q1 2021 | -20.0% | -15.8% | -7.4% | |
| Q4 2020 | -32.5% | -38.9% | -44.3% | |
| Q3 2020 | -0.6% | -1.9% | +12.0% | |
| Q2 2020 | +0.0% | +8.0% | -13.6% | |
| Q1 2020 | -12.2% | -7.3% | +2.1% | |
| Q4 2019 | +18.5% | -4.5% | -22.0% | |
| Q3 2019 | -72.2% | -68.1% | -61.3% | |
| Q2 2019 | +19.0% | +79.9% | +96.1% | |
| Q1 2019 | -31.2% | -34.2% | -43.2% | |
| Q4 2018 | +0.3% | +4.7% | -9.9% | |
| Q3 2018 | +13.8% | +3.8% | -2.6% | |
| Q2 2018 | -1.2% | -1.1% | +2.5% | |
| Q1 2018 | +11.6% | +15.2% | +19.6% | |
| Q4 2017 | +1.9% | +12.7% | +86.2% | |
| Q3 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q1 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro